Daiichi Sankyo has announced a new cancer research collaboration with Puma Biotechnology and the Memorial Sloan Kettering Cancer Center.

The preclinical research alliance will explore the combination of Daiichi Sankyo's investigational antibody drug conjugate DS-8201 and Puma Biotechnology's irreversible pan-HER tyrosine kinase inhibitor neratinib in HER2-mutated or HER2-positive solid tumours.

“Daiichi Sankyo is partnering with Puma Biotechnology and the Memorial Sloan Kettering Cancer Center to study a new combination therapy for cancer.“

Isogenic models and established patient-derived xenograft models will be used to assess the susceptibility of HER2-mutated or HER2-positive cancers to these HER2-targeting therapies, allowing them to determine mechanisms of action and resistance, and evaluate the potential for synergistic combinations.

It is hoped that combining agents that address different and complementary pathways will help to maximise the potential for each agent to effectively combat cancer.

Tom Held, vice-president and global head of the antibody drug conjugate task force at Daiichi Sankyo, said: "We are excited to join forces with Memorial Sloan Kettering and Puma to advance the understanding of combining HER2-targeted therapies to potentially treat various forms of HER2-mutated cancer."

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.